AEX 41
Alternative Names: AEX-41Latest Information Update: 12 Mar 2024
At a glance
- Originator Aexon Labs
- Class Antidementias; Neuroprotectants; Sleep disorder therapies
- Mechanism of Action Orexin receptor type 1 agonists; Orexin receptor type 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders
Most Recent Events
- 26 Feb 2024 Preclinical trials in CNS disorders in USA (unspecified route) (Aexon Labs pipeline, February 2024)